. 2016 Nov 15;6:36969. doi: 10.1038/srep36969

Table 3. IC ₅₀ values for the inhibitory effects of the test drugs (compounds and reference inhibitors) on the enzymatic activity of human COX-1 (rational assays selected by our modeling) and human MAO-B (control assays not selected by the modeling).

DRUG	IC₅₀hCOX-1 (μM)	IC₅₀ hMAO-B (μM)
Lapatinib	^a19.5 % inhibition at 25 μM	**
SB-202190	23.59 ± 3.53	**
RO-316233	25.35 ± 3.80	**
GW786460X	**	**
Indirubin-3′-monoxime	^a28 % inhibition at 25 μM	**
Iproniazide (Reference inhibitor)		7.54 ± 0.36
Selegiline (Reference inhibitor)		0.019 ± 0.001
FR122047 (Reference inhibitor)	0.094 ± 0.006
Indomethacin (Reference inhibitor)	12.16 ± 1.16
Diclofenac (Reference inhibitor)	18.23 ± 1.73

Each IC₅₀ value is the mean ± S.E.M. from three experiments (n = 3). ** Inactive at 100 μM (highest concentration tested). ^a % enzymatic inhibition at 25 μM (compounds precipitated at higher concentrations).

Table 3. IC 50 values for the inhibitory effects of the test drugs (compounds and reference inhibitors) on the enzymatic activity of human COX-1 (rational assays selected by our modeling) and human MAO-B (control assays not selected by the modeling).

Table 3. IC ₅₀ values for the inhibitory effects of the test drugs (compounds and reference inhibitors) on the enzymatic activity of human COX-1 (rational assays selected by our modeling) and human MAO-B (control assays not selected by the modeling).